Illumina Inc (ILMN)
Healthcare | Biotechnology
CEO: Francis A. deSouza
Illumina Inc receives a in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Illumina Inc's valuation score is comprised of a P/E ratio of 35.2x, a P/B ratio of 10.2x, a P/S ratio of 10.7x, and an EV/EBITDA ratio of 22.2x. .
WARREN BUFFETT RANKING
Illumina Inc ranks 234 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Illumina Inc appears to have a durable competitive advantage within the Healthcare sector.
Illumina Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 29.19x, a debt/equity ratio of 40% and a Moat Rank of 42 translate to a strong Financial Strength score.
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 28.98% over the last 12 months. This performance is strong compared to other stocks in the S&P 500, earning it a rank of 87.
VALUE + YIELD
Illumina Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology.
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. Its 37.7% 5 year annualized EPS growth, 17.8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 11.3% speak to its impressive growth ranking.